Literature DB >> 7779120

Autoimmune response to the spliceosome. An immunologic link between rheumatoid arthritis, mixed connective tissue disease, and systemic lupus erythematosus.

W Hassfeld1, G Steiner, A Studnicka-Benke, K Skriner, W Graninger, I Fischer, J S Smolen.   

Abstract

OBJECTIVE: To assess the significance of autoantibodies to RA33, the A2 protein of the heterogeneous nuclear ribonucleoproteins (hnRNP), and to the related hnRNP proteins A1, B1, and B2 in rheumatic diseases.
METHODS: Using a partially purified preparation of hnRNP-A and hnRNP-B proteins, sera from 303 patients with various rheumatic diseases were investigated by immunoblotting. For the analysis of cross-reactivities, autoantibodies were affinity purified by blot elution.
RESULTS: Anti-A2/RA33 was found in 35% of rheumatoid arthritis (RA) patients, 38% of mixed connective tissue disease (MCTD) patients, 23% of systemic lupus erythematosus (SLE) patients, and, apart from single exceptions, not in patients with other rheumatic diseases. All anti-A2/RA33-positive sera were also reactive with B1 and B2, and anti-A2/RA33 antibodies cross-reacted with both proteins. Antibodies to hnRNP-A1 were found less frequently; moreover, the majority of anti-A1-positive sera also contained anti-A2/RA33 antibodies. In anti-A1, anti-A2/RA33 double-positive sera, cross-reactivity between the 2 antibodies was generally observed. In SLE patients, the presence of anti-A2/RA33 was correlated with the presence of anti-(U1) small nuclear RNP (snRNP) and anti-Sm (P < 0.0001 and P < 0.005, respectively), but there was no evidence for cross-reactivity between antibodies to hnRNP and antibodies to snRNP antigens.
CONCLUSION: Since both hnRNPs and snRNPs are essential components of the spliceosome, the data show that the immune systems of patients with RA, SLE, and MCTD react to this functional complex. However, compared with MCTD and SLE patients, RA patients have a more restricted immune response to the spliceosome: they react to hnRNP proteins, particularly to hnRNP-A2/RA33, but not to snRNPs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7779120     DOI: 10.1002/art.1780380610

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  23 in total

1.  Key residues revealed in a major conformational epitope of the U1-70K protein.

Authors:  E Welin Henriksson; M Wahren-Herlenius; I Lundberg; E Mellquist; I Pettersson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-07       Impact factor: 11.205

Review 2.  Autoantibodies and overlap syndromes in autoimmune rheumatic disease.

Authors:  E C Jury; D D'Cruz; W J Morrow
Journal:  J Clin Pathol       Date:  2001-05       Impact factor: 3.411

3.  Anti-A2/RA33 autoantibodies are directed to the RNA binding region of the A2 protein of the heterogeneous nuclear ribonucleoprotein complex. Differential epitope recognition in rheumatoid arthritis, systemic lupus erythematosus, and mixed connective tissue disease.

Authors:  K Skriner; W H Sommergruber; V Tremmel; I Fischer; A Barta; J S Smolen; G Steiner
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

Review 4.  Clinical relevance of autoantibodies in systemic rheumatic diseases.

Authors:  M J Fritzler
Journal:  Mol Biol Rep       Date:  1996       Impact factor: 2.316

5.  Natural HLA-B*2705 protein ligands with glutamine as anchor motif: implications for HLA-B27 association with spondyloarthropathy.

Authors:  Susana Infantes; Elena Lorente; Eilon Barnea; Ilan Beer; Alejandro Barriga; Fátima Lasala; Mercedes Jiménez; Arie Admon; Daniel López
Journal:  J Biol Chem       Date:  2013-02-19       Impact factor: 5.157

6.  Increased serum and synovial fluid antibodies to immunoselected peptides in patients with rheumatoid arthritis.

Authors:  A Dybwad; O Førre; M Sioud
Journal:  Ann Rheum Dis       Date:  1996-07       Impact factor: 19.103

7.  Clinical and serological associations of autoantibodies to GW bodies and a novel cytoplasmic autoantigen GW182.

Authors:  Theophany Eystathioy; Edward K L Chan; Ken Takeuchi; Michael Mahler; LeeAnne M Luft; Douglas W Zochodne; Marvin J Fritzler
Journal:  J Mol Med (Berl)       Date:  2003-11-04       Impact factor: 4.599

8.  Significantly increased antibody response to heterogeneous nuclear ribonucleoproteins in cerebrospinal fluid of multiple sclerosis patients but not in patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis.

Authors:  Motohiro Yukitake; Eisaburo Sueoka; Naoko Sueoka-Aragane; Akemi Sato; Hiromi Ohashi; Yusuke Yakushiji; Mineki Saito; Mitsuhiro Osame; Shuji Izumo; Yasuo Kuroda
Journal:  J Neurovirol       Date:  2008-04       Impact factor: 2.643

9.  Autoantibody signatures involving glycolysis and splicesome proteins precede a diagnosis of breast cancer among postmenopausal women.

Authors:  Jon J Ladd; Timothy Chao; Melissa M Johnson; Ji Qiu; Alice Chin; Rebecca Israel; Sharon J Pitteri; Jianning Mao; Mei Wu; Lynn M Amon; Martin McIntosh; Christopher Li; Ross Prentice; Nora Disis; Samir Hanash
Journal:  Cancer Res       Date:  2012-12-26       Impact factor: 12.701

10.  Epidermal loss of JunB leads to a SLE phenotype due to hyper IL-6 signaling.

Authors:  Pamina Pflegerl; Paul Vesely; Brigitte Hantusch; Michaela Schlederer; Rainer Zenz; Elke Janig; Günter Steiner; Arabella Meixner; Peter Petzelbauer; Peter Wolf; Afschin Soleiman; Gerda Egger; Richard Moriggl; Tadamitsu Kishimoto; Erwin F Wagner; Lukas Kenner
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.